Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press22010.17650/1994-4098-2010-0-1-68-71GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕA new view of treatment for ovarian cancerНовый взгляд на лечение рака яичниковKhokhlovaS. V.ХохловаС. В.
Russian Federation
svkhokhlova@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва250220101687125082014250820142010https://ojrs.abvpress.ru/ojrs/article/view/220

The basic investigations in the past year are dedicated to search for new markers for the screening and early diagnosis of ovarian can- cer, to the definition of a role of retroperitoneal lymph dissection, the time of initiation of second-line treatment in the marker progres- sion of this disease, to the development of different modified regimens in both first-line therapy and recurrent ovarian cancer.

Основные работы последнего года посвящены поиску новых маркеров для скрининга и ранней диагностики рака яичников, определению роли забрюшинной лимфодиссекции, сроков начала лечения 2-й линии при маркерном прогрессировании данного заболевания, разработке различных модифицированных режимов как в терапии 1-й линии, так и при рецидивах рака яичника.

ovarian cancermarkersgenetic characteristicsрак яичниковмаркерыгенетическая характеристика1. Winer E., Gralow J. et al. Успехи клинической онкологии 2008: наиболее значимые достиженияWiner E., Gralow J. et al. Успехи клинической онкологии 2008: наиболее значимые достиженияв лечении, профилактике и скрининге онкологических заболеваний. J Clin Oncol 2009;3(2).2. Ovarian cancer. R. Bast, M. Markman, eds. 2009.Ovarian cancer. R. Bast, M. Markman, eds. 2009.3. Rustin G.,Van der Burg M. A randomized trial in ovarian cancer of early treatment of relapse based on CA-125 level alone versus delayed treat- ment based on conventional clinical indi- cators (MRC OV05/EORTC 55955 tri- als). J Clin Oncol 2009;27:18. Abstr 1.Rustin G.,Van der Burg M. A randomized trial in ovarian cancer of early treatment of relapse based on CA-125 level alone versus delayed treat- ment based on conventional clinical indi- cators (MRC OV05/EORTC 55955 tri- als). J Clin Oncol 2009;27:18. Abstr 1.4. Kim H., Ju W. et al. The efficacy of systemic lymphadenonectomy for overal survi val in epithelial ovarian cancer. A systematic review and meta-analysis by KOGYMAG. J Clin Oncol 2009;27. Abstr 16509.Kim H., Ju W. et al. The efficacy of systemic lymphadenonectomy for overal survi val in epithelial ovarian cancer. A systematic review and meta-analysis by KOGYMAG. J Clin Oncol 2009;27. Abstr 16509.5. Pignata S., Scambia G., et al. Carboplatin plus paclitaxel versus carbo- platin plus liposomal doxorubicin in patients with advanced ovarian cancer; MITO-2. ASCO 2009. Abstr LBA 5508.Pignata S., Scambia G., et al. Carboplatin plus paclitaxel versus carbo- platin plus liposomal doxorubicin in patients with advanced ovarian cancer; MITO-2. ASCO 2009. Abstr LBA 5508.6. Pujade-lauraine S., Mahner J. et al. A randomized, phase III study of carbo- platin and pegylated liposomal doxoru- bicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian can- cer; CALYPSO (GCIG). ASCO 2009. Abstr LBA5509.Pujade-lauraine S., Mahner J. et al. A randomized, phase III study of carbo- platin and pegylated liposomal doxoru- bicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian can- cer; CALYPSO (GCIG). ASCO 2009. Abstr LBA5509.7. Isonishi S., Yasuda F. et al. Randomised phase III trial of conven- tional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 2008;26:1642—9. Abstr 5506.Isonishi S., Yasuda F. et al. Randomised phase III trial of conven- tional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 2008;26:1642—9. Abstr 5506.8. Burg. J., Jannssen P. et al. Multicenter randomized phase III trial of 3- weekly paclitaxel/platinum versus weekly paclitaxel/platinum induction therapy followed by 3-weekly mainte- nance therapy in advanced epithelial ovarian cancer. ASCO 2009. Abstr 5538.Burg. J., Jannssen P. et al. Multicenter randomized phase III trial of 3- weekly paclitaxel/platinum versus weekly paclitaxel/platinum induction therapy followed by 3-weekly mainte- nance therapy in advanced epithelial ovarian cancer. ASCO 2009. Abstr 5538.9. Gladieff L., Lortholary A. et al. Weekly paclitaxel as single agent or in combination with weekly topotecan or carboplatin in patients with resistant ovarian cancer. The phase II CARTAX- HY randomized trial from GINECO. ASCO 2009. Abstr.5557Gladieff L., Lortholary A. et al. Weekly paclitaxel as single agent or in combination with weekly topotecan or carboplatin in patients with resistant ovarian cancer. The phase II CARTAX- HY randomized trial from GINECO. ASCO 2009. Abstr.555710. Sehouli J., Oskay-Oezcelik G. et al. Topotecan weekly versus routine 5-day schedule in patients with platinum-resist- ant ovarian cancer (TOWER). ASCO 2009. Abstr 5553.Sehouli J., Oskay-Oezcelik G. et al. Topotecan weekly versus routine 5-day schedule in patients with platinum-resist- ant ovarian cancer (TOWER). ASCO 2009. Abstr 5553.11. Odunsi K., Ghamande S. et al. A phase II. Pharmacokinetic and phar- macodynamic study of weekly docetaxel in patients with platinum-resistant ovarian cancer. ASCO 2009. Abstr 16531.Odunsi K., Ghamande S. et al. A phase II. Pharmacokinetic and phar- macodynamic study of weekly docetaxel in patients with platinum-resistant ovarian cancer. ASCO 2009. Abstr 16531.12. Burger R., Still M. et al. Phase II trial of bevacizumab in persist- ent or recurrent epithelial ovarian cancer or primary peritoneal cancer. ASCO 2005. Abstr 5009.Burger R., Still M. et al. Phase II trial of bevacizumab in persist- ent or recurrent epithelial ovarian cancer or primary peritoneal cancer. ASCO 2005. Abstr 5009.13. Cannistra S., Matulonis U. et al. Bevacizumab in pts with advanced plat- inum-resistant ovarian cancer. ASCO 2006. Abste 5006.Cannistra S., Matulonis U. et al. Bevacizumab in pts with advanced plat- inum-resistant ovarian cancer. ASCO 2006. Abste 5006.14. Crijns A., Boezen H. et al. Prognostic factors in ovarian cancer: cur- rent evidence and future prospects. Eur J Cancer Suppl 2005;1(6):127—45.Crijns A., Boezen H. et al. Prognostic factors in ovarian cancer: cur- rent evidence and future prospects. Eur J Cancer Suppl 2005;1(6):127—45.15. Bookman M., Darcy K. et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab in pts with recurrent or refractory ovarian or primary peritoneal carcinoma with over- expression of Her-2. J Clin Oncol 2003;21:283—90.Bookman M., Darcy K. et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab in pts with recurrent or refractory ovarian or primary peritoneal carcinoma with over- expression of Her-2. J Clin Oncol 2003;21:283—90.16. Guastalla J.P., Allouache D.et al. Her-2 overexpression and amplification ovarian cancer. ASCO 2007. Abstr 5559.Guastalla J.P., Allouache D.et al. Her-2 overexpression and amplification ovarian cancer. ASCO 2007. Abstr 5559.17. Amler L., Makhija S. et al. HER pathway gene expression analysis in a phase II study of pertuzumab + Gemcitabine v.s. Gemcitabine + placebo in patients with platinum- resistant epithelial ovarian cancer. ASCO 2008. Abstr 5552.Amler L., Makhija S. et al. HER pathway gene expression analysis in a phase II study of pertuzumab + Gemcitabine v.s. Gemcitabine + placebo in patients with platinum- resistant epithelial ovarian cancer. ASCO 2008. Abstr 5552.18. Cass I., Baldnin R. Improved survival in women with BRCA- associated ovarian carcinoma. Cancer 2009;97:2187—95.Cass I., Baldnin R. Improved survival in women with BRCA- associated ovarian carcinoma. Cancer 2009;97:2187—95.19. Tan D., Rothermundt C. et al. Клинические особенности BRCA- синдрома при раке яичников. J Clin Oncol 2008;26:5530—6.Tan D., Rothermundt C. et al. Клинические особенности BRCA- синдрома при раке яичников. J Clin Oncol 2008;26:5530—6.20. Auden M., Penson R. et al. Phase II trial of the oral PARP inhibitor olaparibAZD 2281) in BRCA-deficient advanced ovarian cancer. ASCO 2009. Abstr 5500.Auden M., Penson R. et al. Phase II trial of the oral PARP inhibitor olaparibAZD 2281) in BRCA-deficient advanced ovarian cancer. ASCO 2009. Abstr 5500.21. Carser J., Quinn J et al. BRCA1 protein expression as a predictor of outcome following chemotherapy in sporadic epithelial ovarian cancer. ASCO 2009. Abstr 5527.Carser J., Quinn J et al. BRCA1 protein expression as a predictor of outcome following chemotherapy in sporadic epithelial ovarian cancer. ASCO 2009. Abstr 5527.